NeuroPace, Inc. (NASDAQ:NPCE) Shares Purchased by JPMorgan Chase & Co.

JPMorgan Chase & Co. raised its holdings in NeuroPace, Inc. (NASDAQ:NPCE) by 440.4% in the fourth quarter, Holdings Channel.com reports. The fund owned 64,826 shares of the company’s stock after acquiring an additional 52,829 shares during the period. JPMorgan Chase & Co.’s holdings in NeuroPace were worth $725,000 at the end of the most recent reporting period.

Other large investors also recently made changes to their positions in the company. Palumbo Wealth Management LLC acquired a new stake in NeuroPace during the 4th quarter valued at $129,000. Barclays PLC grew its holdings in shares of NeuroPace by 346.0% during the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after buying an additional 16,007 shares in the last quarter. Financial Advocates Investment Management raised its position in NeuroPace by 27.8% during the fourth quarter. Financial Advocates Investment Management now owns 23,000 shares of the company’s stock valued at $257,000 after buying an additional 5,000 shares during the period. Bank of New York Mellon Corp raised its position in NeuroPace by 21.2% during the fourth quarter. Bank of New York Mellon Corp now owns 29,342 shares of the company’s stock valued at $328,000 after buying an additional 5,133 shares during the period. Finally, State Street Corp lifted its stake in NeuroPace by 9.1% in the 3rd quarter. State Street Corp now owns 155,490 shares of the company’s stock worth $1,084,000 after acquiring an additional 12,912 shares in the last quarter. Institutional investors own 78.83% of the company’s stock.

Insider Transactions at NeuroPace

In other NeuroPace news, major shareholder Ltd. Kck sold 5,270,845 shares of the company’s stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $9.40, for a total transaction of $49,545,943.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Martha Morrell sold 78,334 shares of the company’s stock in a transaction on Friday, February 21st. The shares were sold at an average price of $13.72, for a total value of $1,074,742.48. Following the transaction, the insider now directly owns 81,993 shares in the company, valued at $1,124,943.96. This trade represents a 48.86 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 22.20% of the company’s stock.

NeuroPace Price Performance

Shares of NASDAQ:NPCE opened at $11.98 on Wednesday. The firm has a market capitalization of $392.38 million, a PE ratio of -11.98 and a beta of 2.03. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. NeuroPace, Inc. has a 1-year low of $5.45 and a 1-year high of $15.11. The business’s 50 day moving average is $11.68 and its 200-day moving average is $10.96.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.07. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. The firm had revenue of $21.47 million during the quarter, compared to analyst estimates of $21.14 million. Sell-side analysts predict that NeuroPace, Inc. will post -1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on NPCE. Cantor Fitzgerald upped their target price on NeuroPace from $19.00 to $20.00 and gave the company an “overweight” rating in a report on Wednesday, March 5th. Wells Fargo & Company upped their price objective on shares of NeuroPace from $13.00 to $17.00 and gave the company an “overweight” rating in a research note on Thursday, January 30th. Finally, UBS Group began coverage on shares of NeuroPace in a research report on Tuesday, January 21st. They issued a “buy” rating and a $17.00 target price for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $15.20.

About NeuroPace

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.